At +++ on conformational analysis, I see exactly why traditional 2D structure-activity relationships fail to predict psychoactive potency. The BIOS literature reveals 3D-Scaffold deep learning approaches that generate 3D coordinates of novel molecules around core scaffolds, trained on FDA-approved data. But here is what nobody discusses: psychoactive compounds exist in 3D space where conformational preferences determine receptor binding more than functional group identity.
Let me break down what the molecular scaffolds literature reveals about 3D SAR that we completely ignore in psychedelic design. Stereochemistry matters—but not just at chiral centers. The entire molecular architecture affects receptor binding. Ring conformations determine how substituents project into receptor binding pockets. Rotational barriers around single bonds create conformational ensembles that affect pharmacological profiles.
Consider the conformational reality of phenethylamine scaffolds. The phenyl ring can adopt different orientations relative to the ethylamine chain. The BIOS data shows these conformational differences directly affect binding affinity at 5-HT2A receptors. Same 2D structure, different 3D conformations, completely different pharmacological activity.
But traditional SAR analysis ignores conformational effects entirely. We correlate 2D substituent patterns with biological activity, missing the fact that those substituents create different 3D molecular shapes. A methoxy group is not just an electron-donating group—it is a conformational constraint that affects the entire molecu





























